{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:49:18Z","timestamp":1767192558113,"version":"build-2065373602"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy. However, immune-related adverse events (irAEs), particularly hematologic toxicities, remain rare but potentially life-threatening complications. Among these, autoimmune hemolytic anemia (AIHA) induced by ICIs is a clinically significant yet underrecognized condition. We report a rare case of ICI-induced AIHA concomitant with thrombocytopenia in an elderly female patient with advanced gastric cancer who had undergone immune monotherapy.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>An 84-year-old female with unresectable, PD-L1\u2013high (combined positive score [CPS] = 55) advanced gastric adenocarcinoma developed a rare case of recurrent immune checkpoint inhibitor associated autoimmune hemolytic anemia and thrombocytopenia after sequential treatment with three ICIs: sintilimab (anti\u2013PD-1), cadonilimab (a bispecific PD-1\/CTLA-4 antibody), and ivonescimab (a bispecific PD-1\/VEGF antibody). Initially, sintilimab monotherapy induced partial tumor regression; however, the patient later developed transfusion-dependent anemia and severe thrombocytopenia. Bone marrow aspiration revealed erythroid aplasia and characteristic teardrop poikilocytes, suggesting marrow stress or fibrosis. Reintroduction of ICIs triggered recurrent hematologic toxicity, pointing to a class-wide immune-mediated mechanism. Despite aggressive treatment with glucocorticoids, red blood cell and platelet transfusions, and comprehensive supportive care, the cytopenias persisted, and imaging confirmed disease progression. Ultimately, immune-related hematologic toxicity led to multiorgan failure and the patient\u2019s death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underscores the diagnostic complexity and therapeutic challenges associated with immune checkpoint inhibitor induced autoimmune hemolytic anemia in elderly patients, particularly those experiencing immunosenescence and possessing limited hematopoietic reserve. The mechanisms underlying this phenomenon remain poorly understood, highlighting the urgent need for mechanistic investigations, individualized immunotherapeutic strategies, and vigilant hematologic monitoring in vulnerable populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1679817","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:46:36Z","timestamp":1761119196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Challenges in immunotherapy for the elderly: a case of refractory ICI-induced AIHA and thrombocytopenia in advanced gastric cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Mingxin","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongxuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yandong","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhui","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors \u2013 a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00946","article-title":"The changing landscape of autoimmune hemolytic anemia","volume":"11","author":"Barcellini","year":"2020","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll","year":"2022","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: A review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00530","article-title":"Immune-related adverse events: A case-based approach","volume":"9","author":"Connolly","year":"2019","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.12.001","article-title":"Autoimmune hemolytic anemia: diagnosis and differential diagnosis","volume":"36","author":"Scheckel","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000439002","article-title":"New insights in the pathogenesis of autoimmune hemolytic anemia","volume":"42","author":"Barcellini","year":"2015","journal-title":"Transfus Med Hemother"},{"key":"B9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (Icis); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.594558","article-title":"Sintilimab: A promising anti-tumor pd-1 antibody","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent pd-1\/ctla-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"mAbs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008037","article-title":"Phase 1a dose escalation study of ivonescimab (Ak112\/smt112), an anti-pd-1\/vegf-a bispecific antibody, in patients with advanced solid tumors","volume":"12","author":"Frentzas","year":"2024","journal-title":"J ImmunoTherapy Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091537","article-title":"A room for long-lived plasma cell contribution in immune cytopenias","volume":"17","author":"Don","year":"2025","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.946630","article-title":"Early-onset autoimmune hemolytic anemia from pembrolizumab in a patient with metastatic lung cancer: A case report","volume":"26","author":"Adeoye","year":"2025","journal-title":"Am J Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2016.1138219","article-title":"Expansion of cd8+ Cells in autoimmune hemolytic anemia","volume":"49","author":"Smirnova","year":"2016","journal-title":"Autoimmunity"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/trf.18270","article-title":"Vesiculation as potential novel pathogenic mechanism in autoimmune hemolytic anemia","volume":"65","author":"de Boer","year":"2025","journal-title":"Transfusion"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01528-3","article-title":"Immune checkpoint inhibitors in geriatric oncology","volume":"26","author":"Cook","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/ajh.27721","article-title":"Mixed autoimmune hemolytic anemia: A systematic review of epidemiology, clinical characteristics, therapies, and outcomes","volume":"100","author":"Jacobs","year":"2025","journal-title":"Am J Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101746","article-title":"Immune checkpoint inhibitor-induced autoimmune hemolytic anemia in endometrial cancer","volume":"59","author":"Danziger","year":"2025","journal-title":"Gynecologic Oncol Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S499806","article-title":"Integration of scrna-seq and bulk rna-seq identifies circadian rhythm disruption-related genes associated with prognosis and drug resistance in colorectal cancer patients","volume":"14","author":"Tao","year":"2025","journal-title":"Immunotargets Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1679817\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:46:40Z","timestamp":1761119200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1679817\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2025.1679817"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1679817","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1679817"}}